Vertex Pharmaceuticals (MA) (VRTX) Reports Third Quarter 2013 Financial Results and Provides Financial Outlook for 2014
10/29/2013 6:56:52 AM
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2013. Vertex reported total third quarter 2013 revenues of $222 million, including net product revenues of $101 million from KALYDECOTM (ivacaftor) and $86 million from INCIVEK® (telaprevir). The GAAP net loss attributable to Vertex was $(124.1) million, or $(0.54) per share, for the third quarter of 2013, including certain charges of $49.7 million, comprised primarily of stock-based compensation expense and restructuring charges.
Help employers find you! Check out all the jobs and post your resume.
comments powered by